GLP-2 augments the adaptive response to massive intestinal resection in rat.
To determine whether treatment with a potent protease-resistant analog of human glucagon-like peptide 2 (GLP-2) might augment the adaptive response to massive intestinal resection, rats were divided into resected, which had 75% of the midjejunoileum removed, sham-resected, and nonsurgical groups. Within each group, animals were assigned to 21 days of treatment with the drug (0.1 micrograms/g of the GLP-2 analog in phosphate-buffered saline) or vehicle alone subcutaneously twice daily. Food intake; weight gain; jejunal and ileal diameters, total and mucosal wet weights per centimeter, crypt depths, and villus heights; mucosal sucrase activity, milligrams of protein per centimeter, and micrograms of DNA per centimeter; and D-xylose absorption were measured. There was a significant increase in diameter, total and mucosal wet weights per centimeter, crypt-villus height, sucrase activity, milligrams of protein per centimeter and micrograms of DNA per centimeter in both the jejunum and ileum in response to resection and a significant additive response to the GLP-2 analog in the jejunum but not in the ileum. The ratio of milligrams of protein per centimeter to micrograms of DNA per centimeter of mucosa was not different among groups, consistent with hyperplasia. D-Xylose absorption was significantly reduced in response to resection; however, the GLP-2 analog enhanced the absorptive capacity in control animals and restored the absorptive capacity in resected animals. Thus the GLP-2 analog induces mucosal hyperplasia and enhances the rate and magnitude of the proximal intestinal adaptive response to massive resection.
Scott
R B
RB
Gastrointestinal Research Group, Faculty of Medicine, The University of Calgary, Calgary, Alberta, Canada T2N 1N4.
Kirk
D
D
MacNaughton
W K
WK
Meddings
J B
JB
D000222:Adaptation, Physiological / Q000187:drug effects*; D000714:Anastomosis, Surgical; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004247:DNA / Q000378:metabolism; D002149:Energy Intake; D005768:Gastrointestinal Hormones / Q000494:pharmacology; D053767:Glucagon-Like Peptide 2; D004763:Glucagon-Like Peptides; D006801:Humans; D007082:Ileum / Q000502:physiology* / Q000601:surgery*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000502:physiology* / Q000601:surgery; D007583:Jejunum / Q000502:physiology* / Q000601:surgery*; D009929:Organ Size; D010455:Peptides / Q000494:pharmacology*; D010539:Permeability; D011506:Proteins / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013393:Sucrase / Q000378:metabolism
D005768:Gastrointestinal Hormones; D053767:Glucagon-Like Peptide 2; D010455:Peptides; D011506:Proteins; D004763:Glucagon-Like Peptides; D004247:DNA; D013393:Sucrase